April 2, 2026
Biotech battles: A price war in obesity drugs, a surge in Q1 M&A, and an investor plea to Trump's FDA over rare disease drug flexibility.
March 26, 2026
Lilly's M&A struggles, Merck's $7B Terns buy, Wave's weight loss drug falters, and Allogene's novel off-the-shelf CAR-T approach.
March 20, 2026
Biotech news on obesity drugs and Lilly's risks, plus an interview with Stelios Papadopoulos on the FDA's woes, China's rise, and innovation.
March 12, 2026
Prasad exits the FDA, Novo settles with Hims, and a deep dive into biotech VC Boris Nikolic's comeback despite his deep ties to Jeffrey Epstein.
March 5, 2026
This week: The FDA's tough stance on sham surgeries for gene therapy trials, and Spire Therapeutics aims to breach the IBD efficacy ceiling.
February 26, 2026
Biotech update: M&A is simmering, the FDA's rare disease stance is creating turmoil, and Lilly's lead over Novo in the obesity market widens.
February 19, 2026
FDA reverses on Moderna's flu shot, Compass's psychedelic drug shows promise, and Hims faces lawsuits over its compounded weight-loss pill.
February 12, 2026
The FDA's unusual refusal to review Moderna's mRNA flu vaccine sparks controversy over regulatory unpredictability and political influence.
February 5, 2026
GLP-1 wars heat up with divergent Lilly/Novo outlooks, Casgevy's rollout stalls on cell collection, & a psychedelic drug hits a WH roadblock.
February 3, 2026
Lipitor's journey from blockbuster cholesterol drug to medical controversy, questioning the true benefit versus risk for millions.
January 29, 2026
Huntington's advocate Lauren Holder details the community's fight for Unicure's gene therapy after a shocking FDA setback on its approval path.
January 22, 2026
A measles outbreak threatens the U.S.'s elimination status, while hospitals brace for Medicaid cuts and navigate a complex political landscape.
January 14, 2026
At JPM, Novo CEO talks obesity market strategy & DTC. VC Bob Nelsen covers biotech's future, China competition, and the impact of AI.
January 8, 2026
Big Pharma enters JPM week with a bullish outlook after navigating political threats, fueling M&A expectations amid cautious investor sentiment.
December 18, 2025
Biotech's 2025 review: The market is back, driven by M&A and fading macro risks. Experts discuss GLP-1 pricing, CEO awards, and a 2026 IPO surge.
December 11, 2025
ASH conference highlights, new obesity drug data, and a deep dive into the precarious future of American science under a new political landscape.
